Compass Pathways Publishes Results From Open-Label Phase 2 Study Evaluating Safety And Tolerability Of Single-Dose Of 25 Mg Of Investigational COMP360 Synthetic Psilocybin Treatment In 22 Patients With Post-Traumatic Stress Disorder

Author: Benzinga Newsdesk | September 02, 2025 05:33am

• Open-label Phase 2 study shows a single 25 mg COMP360 psilocybin dose was well tolerated, with no serious adverse events observed, and indicated both rapid and durable improvement in symptoms from baseline observed out to 12 weeks following a single administration
• Findings published in the Journal of Psychopharmacology

Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of results from an open-label Phase 2 study evaluating the safety and tolerability of a single-dose of 25 mg of investigational COMP360 synthetic psilocybin treatment in 22 patients with post-traumatic stress disorder (PTSD). The Phase 2 study findings, previously disclosed in May 2024, show that COMP360 was well tolerated and indicated both rapid and durable improvement in symptoms from baseline observed out to 12 weeks following a single administration. The international Phase 2 study was conducted across three sites in the U.K. and the U.S.

Posted In: CMPS